Stockscreener 앱 받기
19.75
0.18%
0.035
시장 영업 전:
19.71
-0.035
-0.18%
전일 마감가:
$19.71
열려 있는:
$19.55
하루 거래량:
1.05M
Relative Volume:
0.40
시가총액:
$1.72B
수익:
$139.71M
순이익/손실:
$-209.36M
주가수익비율:
-6.6706
EPS:
-2.96
순현금흐름:
$-160.60M
1주 성능:
-0.63%
1개월 성능:
+28.63%
6개월 성능:
+80.16%
1년 성능:
+16.70%
1일 변동 폭
$19.31
$20.03
1주일 범위
$18.36
$20.20
52주 변동 폭
$8.58
$20.20
Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile
명칭
Syndax Pharmaceuticals Inc
전화
781-419-1400
주소
730 THIRD AVENUE, NEW YORK, MA
SNDX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SNDX
Syndax Pharmaceuticals Inc
|
19.75 | 1.71B | 139.71M | -209.36M | -160.60M | -2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-16 | 재개 | H.C. Wainwright | Buy |
| 2025-09-10 | 재개 | Stifel | Buy |
| 2025-09-04 | 재개 | Guggenheim | Buy |
| 2025-08-05 | 재확인 | BTIG Research | Buy |
| 2025-07-10 | 개시 | Goldman | Buy |
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-06-28 | 개시 | Jefferies | Buy |
| 2024-01-31 | 다운그레이드 | Scotiabank | Sector Outperform → Sector Perform |
| 2023-12-22 | 개시 | Mizuho | Buy |
| 2023-10-25 | 개시 | BofA Securities | Buy |
| 2023-10-11 | 개시 | Goldman | Buy |
| 2023-07-27 | 개시 | Scotiabank | Sector Outperform |
| 2023-07-11 | 개시 | Guggenheim | Buy |
| 2023-04-17 | 재개 | BTIG Research | Buy |
| 2023-01-31 | 개시 | Stifel | Buy |
| 2023-01-03 | 개시 | JP Morgan | Overweight |
| 2022-07-28 | 재개 | B. Riley Securities | Buy |
| 2022-04-11 | 개시 | H.C. Wainwright | Buy |
| 2022-02-15 | 개시 | Goldman | Buy |
| 2021-06-04 | 재개 | Robert W. Baird | Outperform |
| 2021-05-25 | 개시 | Citigroup | Buy |
| 2021-02-18 | 개시 | B. Riley Securities | Buy |
| 2020-12-03 | 개시 | Stifel | Buy |
| 2020-05-22 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-05-22 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-05-18 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-05-11 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-01-13 | 재확인 | H.C. Wainwright | Buy |
| 2019-03-08 | 재확인 | H.C. Wainwright | Buy |
| 2019-01-04 | 개시 | Robert W. Baird | Outperform |
| 2018-01-05 | 개시 | B. Riley FBR, Inc. | Buy |
| 2017-03-16 | 개시 | FBR & Co. | Outperform |
| 2017-03-02 | 개시 | Instinet | Buy |
| 2016-10-07 | 개시 | Guggenheim | Buy |
| 2016-03-28 | 개시 | Citigroup | Buy |
| 2016-03-28 | 개시 | JMP Securities | Mkt Outperform |
| 2016-03-28 | 개시 | Morgan Stanley | Overweight |
모두보기
Syndax Pharmaceuticals Inc 주식(SNDX)의 최신 뉴스
Why Syndax Pharmaceuticals Inc. (1T3) stock could rally strongly2025 Macro Impact & Weekly Watchlist for Consistent Profits - Newser
Is Syndax Pharmaceuticals Inc. (1T3) stock undervalued by metricsQuarterly Portfolio Report & Verified Momentum Watchlists - Newser
Is Syndax Pharmaceuticals Inc. (1T3) stock a buy during volatile marketsCPI Data & Safe Capital Growth Tips - Newser
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Syndax Pharmaceuticals (Nasdaq: SNDX) issues inducement stock options for 15,500 shares to new hire - Stock Titan
Is Syndax Pharmaceuticals Inc. (1T3) stock positioned for digital growth eraWeekly Gains Summary & Real-Time Volume Spike Alerts - Newser
Syndax Pharmaceuticals (SNDX) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Is Syndax Pharmaceuticals Inc a good long term investmentEarnings Growth Projections & Maximize Returns With Insights - earlytimes.in
What insider purchases suggest about Syndax Pharmaceuticals Inc. (1T3) stockMarket Movement Recap & High Accuracy Swing Entry Alerts - Newser
Can Syndax Pharmaceuticals Inc. (1T3) stock reach $200 price targetCEO Change & High Return Trade Opportunity Guides - Newser
CFO Goldan Gifts 1,224 Of Syndax Pharmaceuticals Inc [SNDX] - TradingView
Syndax Announces Participation at the 8th Annual Evercore Healthcare Conference - The Manila Times
Syndax Pharmaceuticals (Nasdaq: SNDX) to present fireside chat at 8th Annual Evercore Healthcare Conference - Stock Titan
Geode Capital Management LLC Has $19.20 Million Position in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Will Syndax Pharmaceuticals Inc. stock beat EPS estimates2025 Analyst Calls & Long-Term Investment Growth Plans - BỘ NỘI VỤ
Syndax Pharmaceuticals, Inc. $SNDX is Aisling Capital Management LP's 3rd Largest Position - MarketBeat
Syndax: Early Commercial Momentum Points Toward Strong 2026 Growth - Seeking Alpha
Syndax Pharmaceuticals, Inc. $SNDX Stock Position Boosted by Franklin Resources Inc. - MarketBeat
Barclays Raises Syndax (SNDX) PT to $35 on Positive Management Update, Model Rerating - MSN
Syndax Pharmaceuticals Grows Revenue As Wall Street Stays Bullish - Finimize
10 Most Promising Stocks with Huge Upside Potential - Insider Monkey
Syndax Pharmaceuticals Stock Falls After Data From Mid-Stage Study Of Revumenib In Form Of Blood Cancer - AOL.com
Syndax Pharmaceuticals, Inc. $SNDX Shares Acquired by Rhenman & Partners Asset Management AB - MarketBeat
Syndax Pharmaceuticals (NASDAQ:SNDX) Hits New 12-Month HighShould You Buy? - MarketBeat
Syndax Pharmaceuticals (NASDAQ:SNDX) Trading 10.9% Higher After Analyst Upgrade - MarketBeat
Syndax Pharmaceuticals Shows Rising Price Performance With Jump To 92 RS Rating - MSN
Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target Raised to $35.00 at Barclays - MarketBeat
Barclays Maintains Syndax Pharmaceuticals (SNDX) Overweight Recommendation - Nasdaq
SNDX Analyst Update: Barclays Raises Price Target to $35 | SNDX Stock News - GuruFocus
Syndax Pharmaceuticals stock hits 52-week high at 18.14 USD By Investing.com - Investing.com Canada
Syndax Pharmaceuticals, Inc.'s (NASDAQ:SNDX) Shares Climb 29% But Its Business Is Yet to Catch Up - simplywall.st
Optimistic Investors Push Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Up 29% But Growth Is Lacking - 富途牛牛
Mizuho Securities Reaffirms Their Buy Rating on Syndax Pharmaceuticals (SNDX) - The Globe and Mail
Syndax Pharmaceuticals (NASDAQ:SNDX) Sets New 1-Year HighHere's Why - MarketBeat
Is Syndax Pharmaceuticals Inc. stock poised for growthWeekly Trend Summary & Fast Entry High Yield Stock Tips - newser.com
How Syndax Pharmaceuticals Inc. (1T3) stock compares with tech leadersWeekly Trend Summary & Long Hold Capital Preservation Tips - newser.com
Syndax at Jefferies: Strategic Growth in Hematologic Therapies By Investing.com - Investing.com Canada
Is Syndax Pharmaceuticals Inc. stock attractive for ETFsJuly 2025 Macro Moves & Entry and Exit Point Strategies - newser.com
How Syndax Pharmaceuticals Inc. (1T3) stock gains from tech spendingJuly 2025 Recap & Daily Price Action Insights - newser.com
Why (SNDX) Price Action Is Critical for Tactical Trading - news.stocktradersdaily.com
How Syndax Pharmaceuticals Inc. (1T3) stock trades under stagflationJuly 2025 Summary & Real-Time Market Sentiment Reports - newser.com
Is Syndax Pharmaceuticals Inc. stock reversal real or fakeMarket Activity Recap & Daily Technical Forecast Reports - newser.com
How Syndax Pharmaceuticals Inc. stock performs in stagflation2025 Support & Resistance & Technical Confirmation Trade Alerts - newser.com
A Look at Syndax Pharmaceuticals's Valuation After Revuforj’s FDA Approval and NCCN Inclusion - Sahm
Published on: 2025-11-19 00:07:46 - newser.com
Syndax Pharmaceuticals Launches Promising Phase 3 AML Study with Revumenib - MSN
Syndax Pharmaceuticals Inc (SNDX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.10%
1.10%
자본화:
|
볼륨(24시간):